BioSpace News Archive

Gain Therapeutics, Inc. today presented new pre-clinical data from its Gaucher Disease (GD) program.

Recce Pharmaceuticals Ltd is pleased to report Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) cohort three at 500mg (tenfold increase on cohort one 50mg dose), indicating a good safety and tolerability profile among seven healthy male subjects.

Werewolf Therapeutics, Inc. announced that management will present at the SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022.

JUVÉDERM® VOLBELLA® XC, PART OF THE NUMBER ONE CHOSEN COLLECTION OF FILLERS, IS THE FIRST AND ONLY DERMAL FILLER TO RECEIVE FDA APPROVAL FOR THE IMPROVEMENT OF INFRAORBITAL HOLLOWS.

CereVasc, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial of the eShunt System in patients with normal pressure hydrocephalus (NPH).

Cellphire Therapeutics, Inc. announced today the appointment of Pamela B. Conley , Ph.D. to the company’s Board of Directors.

Immunome, Inc. (Nasdaq: IMNM), today announced in vitro data demonstrating effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two external laboratories (Boston University’s National Emerging Infectious Diseases Laboratories and Washington University1).

Arcturus Therapeutics Holdings Inc. announced that members of the Company’s management team will be participating in the SVB Leerink 11th Annual Global Healthcare Conference 2022.

Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol ® Cyclo™, at WORLD Symposium 2022.

C2i Genomics and Twist Bioscience Corporation today announced a partnership to develop whole-genome cancer reference materials.